Cocco et al.20 have reported in 2018 that six patients with tumours bearing coincident HER2 amplification and mutations, who received extensive pretreatments subsequently, exhibited a statistically significant response to neratinib monotherapy. The gene discussed is ERBB2; the disease is neoplasm.